Natco Pharma zooms 20% as partner's injection gets USFDA nod

New Delhi: Shares of Natco Pharma jumped 20 percent on Wednesday after the US Food and Drug Administration granted approval to the drug major's marketing partner Mylan's injection used for treatment of relapsing forms of multiple sclerosis (MS).

Representational image. Agencies

Representational image. Agencies

The stock soared 20 percent to Rs 954.35 -- its highest trading permissible limit for the day -- on the BSE.

At the NSE, it zoomed 19.99 per cent to touch its upper circuit limit of Rs 952.40.

In terms of equity volume, 2 lakh shares of the company were traded on the BSE and over 4 lakh changed hands at the NSE during the morning trade.

The approval is granted to Glatiramer Acetate in strengths of 40 mg/ml and 20 mg/ml and the product is substitutable generic version of Teva's Copaxone, Natco Pharma said in a regulatory filing on Wednesday.

The launch plans for both will be communicated shortly after concurring with its partner Mylan, it added.

Updated Date: Oct 04, 2017 18:46 PM

Also Watch

Watch: The true stories from Dharavi that inspired Rajinikanth's Kaala
  • Thursday, March 8, 2018 Watch: Cyrus Khan talks about Parkour, jumping across walls and why he hates sitting
  • Thursday, May 31, 2018 Unwind: India's basketball sensation Amjyot Singh has his eyes set on becoming an NBA regular
  • Monday, May 28, 2018 First Day First Showsha — Review of Solo: A Star Wars Story in 10 questions
  • Saturday, May 19, 2018 Social Media Star: Rajkummar Rao and Bhuvan Bam open up about selfie culture, online trolls

Also See